MYC Gene Amplification Frequently Observed in Stomach and Gastroesophageal Junction Cancers, Associated with Male Gender and Diminished Neoadjuvant Treatment Efficacy - Takeaways - MDSpire

MYC Gene Amplification Frequently Observed in Stomach and Gastroesophageal Junction Cancers, Associated with Male Gender and Diminished Neoadjuvant Treatment Efficacy

  • By

  • Ole Biegler

  • Hans-Michael Behrens

  • Jochen Haag

  • Thomas Becker

  • Steffen Markus Heckl

  • Silke Lüschen

  • Christoph Röcken

  • April 24, 2026

  • 0 min

Share

  • 1

    MYC gene amplification is frequently observed in stomach and gastroesophageal junction cancers, particularly in male patients.

  • 2

    Gastric cancer incidence is higher in men, with significant increases in younger populations under 50 years.

  • 3

    MYC amplification correlates with diminished efficacy of neoadjuvant treatment in gastric cancer patients.

  • 4

    The study analyzed a large cohort of Caucasian patients to assess MYC amplification and intratumoral heterogeneity.

  • 5

    Standard treatment for locally advanced gastric cancer includes perioperative FLOT, with ongoing exploration of targeted therapies.

Original Source(s)

MYC Gene Amplification Frequently Observed in Stomach and Gastroesophageal Junction Cancers, Associated with Male Gender and Diminished Neoadjuvant Treatment Efficacy

  • by Ole Biegler, Hans-Michael Behrens, Jochen Haag, Thomas Becker, Steffen Markus Heckl, Silke Lüschen, Christoph Röcken

  • April 24, 2026

Related Content

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy